The α7 nicotinic acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Adult female hooded Lister rats received sub-chronic phencyclidine (PCP) (2 mg/kg) or vehicle i.p. twice daily for 7 days, followed by 7 days' washout. PCP-treated rats then received PNU-120596 (10 mg/kg; s.c.) or saline and were tested in the attentional set-shifting task. Sub-chronic PCP produced a significant cognitive deficit in the extra-dimensional shift (EDS) phase of the task (p < 0.001, compared with vehicle). PNU-120596 significantly improved performance of PCP-treated rats in the EDS phase of the attentional set-shifting task (p < 0.001). In conclusion, these data demonstrate that PNU-120596 improves cognitive dysfunction in our animal model of cognitive dysfunction in schizophrenia, most likely via modulation of α7 nACh receptors.
Introduction
Cognitive deficits in schizophrenia have an important impact on outcome for patients and remain largely untreated by current medication (Keefe et al., 2007) . There is thus a clear need for improvements in therapy of this aspect of the illness. We have demonstrated robust impairments in set-shifting ability measured by impaired performance in the intra/extra-dimensional task using the CANTAB in first-episode psychosis patients (Saleem et al., 2010) . This task assesses rule acquisition and reversal learning, based on visual discrimination of shapes and lines. Our results are supported by other studies showing that patients with schizophrenia show impaired set-shifting ability (Haut et al., 1996; Kolb and Wilshaw, 1983; Pantelis et al., 1999) . The rodent version of the attentional set-shifting task was adapted by Birrell and Brown (2000) and is a useful analogue of the Wisconsin Card Sorting Test (Berg, 1948) . The TURNS initiative has determined that this rodent test can be used in preclinical tests to evaluate new therapeutic strategies (www.turns.ucla.edu) . Initial studies using the perceptual attentional set-shifting task showed that lesions of the medial prefrontal cortex (mPFC) produce a selective deficit in the extra-dimensional shift (EDS) phase (Birrell and Brown, 2000) . In our laboratory we have shown a selective deficit in female rats in the EDS phase following our 7 day sub-chronic phencyclidine (PCP) treatment regime; this deficit was attenuated by clozapine and risperidone, but was unaffected by haloperidol (McLean et al., 2008 ). This PCP model in female rats has been found to induce robust cognitive deficits and neurobiological changes of relevance to schizophrenia, and shows efficacy of a range of novel targets (see Neill et al., 2010 for review).
The most prevalent nicotinic acetylcholine receptors (nAChRs) are the α4β2 and α7 subtypes, both of which show reduced numbers in schizophrenia (Breese et al., 2000; Freedman et al., 1995) . Both of these receptor subtypes play a role in cognitive processing (Chan et al., 2007; Gray and Roth, 2007; Schreiber et al., 2002) . See Leiser et al. 2009 for a recent review of the role of α7 nAChRs in cognitive processing of relevance to schizophrenia. We have recently shown that the α7 nAChR full agonist, PNU-282987, reverses a sub-chronic PCP-induced deficit in two cognitive tests: novel object recognition and operant reversal learning (McLean et al., 2011) . It has been suggested that full nicotinic receptor agonists may provide sub-optimal benefits due to sustained activation and/or desensitisation at the target receptor (Harris et al., 2004; Quick and Lester, 2002; Smith et al., 2002; White and Levin, 2004) ; this dilemma poses a pharmacological problem with respect to long-term therapy. However, we showed that the full α7 nAChR agonist, PNU-282987, was effective in reversing the PCP-induced deficit in novel object recognition following oncedaily administration for 15 days, suggesting that repeated activation of the target over a 15-day period does not evoke tolerance. However, this is relatively short term and does not necessarily reflect the clinical situation, in which patients may have received a specific treatment for months or years.
An alternative approach to enhance α7 nAChR function is by augmenting effects of acetylcholine via positive allosteric modulation (PAM) that can reinforce the endogenous cholinergic tone without directly activating α7 nAChRs (see Maelicke, 2000) . Various molecules have been reported to positively modulate α7 nAChRs, including PNU-120596 (Hurst et al., 2005) , ivermectin (Krause et al., 1998) and galantamine (Zhao et al., 2006) . PNU-120596 represents a novel positive allosteric modulator at the α7 nAChRs, which can increase the maximal agonist-evoked current and slow the decay of the currents in the continued presence of an agonist. The aim of this study was to investigate the efficacy of the selective α7 nAChR positive allosteric modulator, PNU-120596, in a model of relevance to cognitive deficits in schizophrenia, specifically PCP-induced deficits in the perceptual attentional setshifting task.
Materials and methods

Subjects and housing conditions
For this study, 30 adult female hooded Lister rats (Harlan, UK) housed in groups of five were used as subjects. Animals initially weighing 200-220 g were maintained under standard laboratory conditions at a temperature of 21°C (±2°C) and humidity of 40-50%. They were maintained on a 12 h/12 h light/dark cycle (lights on at 07:00 h) and experimental procedures were performed during the light phase. Rats were gradually food deprived to approximately 90% of free-feeding body weight; reduced body weight was maintained by restricting the amount of food (standard laboratory chow, Special Diet Services, Essex, UK) given to each rat per day (12 g/day). The availability of water was not restricted. Experiments were conducted in accordance with the Animals (Scientific Procedures) Act UK (1986), and approved by the University of Bradford ethical review process.
Attentional set-shifting
Rats were trained and tested in the attentional set-shifting procedure as described in detail in McLean et al. (2008) , except rats were counterbalanced equally on odour and digging medium initially in simple discrimination (SD). In all cases, rats were tested in the attentional set-shifting procedure 24 h after training. The first stage of testing was the SD, which was identical to the SD in the training session on the previous day, except new exemplars were used. Testing continued until the rat reached a criterion of six consecutive correct responses. For the compound discrimination (CD), a second dimension was introduced (odour or medium), but the correct and incorrect exemplars remained the same. For the reversals, the exemplars and relevant dimensions remained the same, but the rats had to learn that the previously baited odour was now incorrect and the other odour was now the correct one. New exemplars were used for the intra-dimensional (ID) and extra-dimensional (ED) shifts. The specific exemplars used are shown in Table 1 ; odours were aromatic oils (Bodyshop, UK) and were selected based on a pilot study showing that the oils used did not induce aversive behaviours. For the ED shift, the previously irrelevant parameter (odour or medium) was now relevant.
Drugs
Rats were pre-treated with 2.0 mg/kg PCP or vehicle (0.9% saline) by the intraperitoneal (i.p.) route twice daily for 7 days. Dosing with sub-chronic PCP or vehicle was followed by a washout period of a further 7 days. PCP hydrochloride (Sigma, UK) was dissolved in 0.9% saline. PCP-treated rats were then administered either PNU-120596 (supplied by Johnson and Johnson, Beerse, Belgium) or vehicle (PBS + 5% DMSO + 5% solutol) 30 min prior to testing. All treatment groups were n = 10. PNU-120596 (N-[5chloro-2,4-dimethoxyphenyl]-N′-[5-methyl-3-isoxazo lyl]-urea) was dissolved in PBS containing 5% DMSO (Sigma, UK) and 5% solutol (Johnson and Johnson, Beerse, Belgium), and was given in 1 mL/kg volume via the s.c. route and tested at one dose only of 10 mg/kg. The dose was selected based on efficacy to reverse a sub-chronic PCP deficit in the novel object recognition task in our laboratory, which tested doses of 5, 10 and 20 mg/kg of PNU-120596 and showed greatest efficacy at 10 mg/kg and some efficacy at 20 mg/kg (Idris et al., unpublished observations).
Pharmacokinetics analysis
The plasma and brain pharmacokinetics of PNU-120596 were studied in satellite groups of female hooded Lister rats (~200 g). The compound was administered at 10 mg/kg as reported above, using the same formulation and dose volume as the main pharmacological studies. From each individual animal, (n = 3), blood and brain samples were collected at 15 and 30 min, 1, 2, 4, 7 and 24 h after dose administration. Samples were placed immediately on melting ice and plasma was obtained following centrifugation at 4°C for 10 min at 1900 × g. Tissue samples were homogenized in water (1/9 w/v or + 3 ml if tissue weight < 0.33 g). All samples were shielded from daylight and stored at ≤ -18°C prior to analysis. Plasma and brain samples were analysed using an LC-MS/MS method with a lower limit of quantification of 1.0 ng/mL in both matrices. A limited pharmacokinetic analysis was performed using WinNonlin™ Professional (Version 5.1).
Data and statistical analysis
Data for trials to criterion were analysed by a repeated measures two-way ANOVA using phase as a within-subjects factor and drug treatment as between-subjects factor and post-hoc Bonferroni multiple comparisons test. Post-hoc paired t-tests were carried out to compare difficulty between phases within the same treatment group.
Results
Attentional set-shifting
A repeated measures two-way ANOVA using phase as a withinsubjects factor and drug treatment as between-subjects factor revealed a significant effect of phase [F 6,162 = 33.23; p < 0.001], a significant effect of drug [F 2,27 = 11.01; p < 0.001] and an overall significant interaction [F 2,27 = 6.59; p < 0.01]. A significant increase in trials to criterion in reversal 1 was observed in all treatment groups compared with simple discrimination (p < 0.01; Figure 1 ). A significant increase (p < 0.05) was also observed in the vehicle group in the EDS phase compared with the IDS phase, indicating that an attentional set had been formed. Post-hoc analysis within the treatment groups showed that PCP significantly increased trials to criterion in the EDS phase (p < 0.001) and in reversal 3 (p < 0.01). This deficit was significantly attenuated in the EDS phase by PNU-120596 (10 mg/kg, s.c.; p < 0.001). There was no effect of treatment on time taken to complete the trials (data not shown), suggesting there were no motoric effects of the compound.
Active plasma and brain levels Following s.c. administration of 10 mg/kg PNU-120596 to female hooded Lister rats, rather low mean plasma levels were observed (C max 14.5 ng/mL,) at 0.8 h post dose. As can be seen in Figure 2 and Table 2 , plasma levels were low yet relatively stable across the first 4 h post dose. Area under the concentration time curve (AUC 0-last ) was 167 ng.h/mL. As the compound was administered as a suspension, dissolution at the s.c. injection site was probably rather slow and incomplete. Brain levels were consistent with plasma, indicating a rapid absorption and subsequent distribution (brain/plasma ratio ~1).
Discussion
The current study showed that sub-chronic PCP induced a robust cognitive deficit in attentional set-shifting, and the α7 nAChRpositive allosteric modulator, PNU-120596, selectively attenuated the deficit in the EDS phase of the attentional set-shifting task. Recent studies in our laboratory and elsewhere show that many targets are effective to improve the PCP-induced deficit in a variety of tasks assessing different aspects of cognitive function (for recent reviews see Jones et al., 2011; Neill et al., 2010) . For example, in novel object recognition several atypical antipsychotics, a D 1 receptor agonist, ampakines, glycine uptake inhibitors, 5-HT 2A receptor inverse agonists, a 5-HT 6 receptor antagonist, GABA A receptor agonists and full agonists at α7 nACh receptors are active to reverse the PCP-induced deficit (see Neill et al., 2010 for further details). Clearly, the key question here is which, if any, are effective in the clinic and how valuable the positive animal data are. Inspection of the clinical trials ongoing at schizophreniaresearchforum.org shows that many of these targets are currently in various stages of clinical testing, with varying degrees of success, with patients not always assessed Figure 1 . The effect of acute treatment with PNU-120596 (10 mg/kg, s.c.) in sub-chronic PCP (2 mg/kg, twice daily for 7 days, i.p.) treated rats on total trials to reach criterion in the attentional set-shifting task. All data are expressed as mean ± SEM (n = 10). Data were analysed by repeated two-way ANOVA and post-hoc Bonferroni multiple comparisons test. $ p < 0.05-$$ p < 0.01; significant increase in trials to criterion between stages of the task analysed by a post-hoc paired t-tests. **p < 0.01-***p < 0.001; significant increase in trials to criterion in PCPtreated rats. ### p < 0.001; significant decrease in trials to criterion in PNU-120596-treated rats. for cognitive function. It is therefore still early to correlate preclinical with clinical efficacy, although some data are emerging. For animal models, it will be important to show efficacy across a range of cognitive domains, in more than one model (e.g. in a genetic and pharmacological and/or neurodevelopmental model) to show that efficacy is maintained following chronic treatment and also demonstrate effects on neurobiological measures such as gamma oscillations and parvalbumin. The present results show that the vehicle-treated group required significantly fewer trials to reach criterion in the IDS phase than in the EDS phase, suggesting that an attentional set was formed. In all treatment groups, rats required more trials to reach criterion in reversal 1 compared with the SD stage of the task, suggesting that all groups found reversal 1 more difficult than the previous stages. There was a significant increase in trials required to reach criterion in PCP-treated rats in the EDS stage, suggesting that sub-chronic PCP causes a deficit in attentional setshifting ability. This is in agreement with a previous study in our laboratory (McLean et al., 2008) . This deficit in also seen in patients with schizophrenia and in our first-episode study (Saleem et al., 2010) , strengthening the validity of this model in rats. This result is supported by several studies in other laboratories in which sub-chronic PCP also produces deficits in the EDS phase of the attentional set-shifting task, although ours is the only study to use female rats (Egerton et al., 2008; Goetghebeur and Dias, 2009; Rodefer et al., 2005 Rodefer et al., , 2008 ). In the current study PNU-120596 (10 mg/kg) significantly reversed this PCP-induced deficit in the EDS phase. In addition, PCP significantly increased trials to criterion in reversal 3. Although PNU-120596 did not significantly improve the PCP-induced deficit in reversal 3, the number of trials was decreased from 13.3 to 9.9, a level of responding similar to that of the vehicle-treated group (8.5 trials). Pharmacokinetic analysis revealed that PNU-120596 at 10 mg/kg reached plasma and brain, albeit at relatively low levels. Ideally the pharmacokinetic analysis should have been carried out in satellite PCP-treated rats rather than drug-naive rats. However, as the dose of PCP is low and is followed by a 7-day washout period, it is unlikely to affect the clearance mechanisms of the compound.
Based on an in vitro calcium flux assay (data not shown), the compound shows activity on the human α7 ion channel with an EC50 of 0.16 µM (50 ng/mL). Data for the rodent ion channel are not available, so the assumption is that the activity is comparable across species. In vivo a C max of 14.8 ng/mL (0.05 µM) and an AUC 0-last of 167 ng.h/ml (0.53 µM.h) were observed. The concentrations observed in vivo are therefore within the range for in vitro activity (assumption human/rat as above). At this point we do not fully understand the pharmacokinetic/pharmacodynamic (PK/PD) relationship of this molecule or mechanism, i.e. a maximum plasma concentration or an AUC driving the response. Further studies are clearly required to elucidate the full PK/PD profile and will be the subject of further studies.
In support of our data, a recent study found that the α7 nAChR partial agonist, RG3487, improved sub-chronic PCP-induced deficits in attentional set-shifting in male Long-Evans rats (Wallace et al., 2011) . In addition, nicotine was found to improve auditory and visual shift trials in male Sprague-Dawley rats (Brown et al., 2010 ). An α7 nAChR full agonist, compound A ((R)-N-(1-azabicyclo[2.2.2] oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide), has also been Individual (animals B1, B2, B3) and mean plasma concentrations (ng/mL) and some basic pharmacokinetic parameters after single s.c. administration at 10 mg/kg of PNU-120596 in female hooded-Lister rats. Plasma (and brain) samples were collected at different time intervals after compound administration. Concentrations of PNU-120596 were determined as described in materials and methods and plotted as a function of time.
shown to improve olfactory working memory in the odour span task in uncompromised rats (Rushforth et al., 2010) . We have also found the full agonist, PNU-282987, to reverse sub-chronic PCP-induced deficits in the novel object recognition task (McLean et al., 2011) . For a detailed review of the effects of nicotine in animal models of attention see Levin et al. (2011) . PAMs of α7 nAChRs have been classified as either type 1 or type 2 compounds; type 1 compounds predominantly affect the peak current response, whereas type 2 compounds affect both peak current responses and the kinetics of agonist-evoked responses (Bertrand and Gopalakrishnan, 2007) . It has been shown that PNU-120596 causes potentiation of agonist-evoked α7 receptor responses by binding within the nAChR transmembrane region, therefore characterizing it as a type 2 PAM (Young et al., 2008) . The attenuating effects of PNU-120596 in our cognitive task are supported by a study showing that PNU-120596 increased the potency of ACh by ~10-fold and reversed an amphetamine-induced deficit in auditory gating in rats (Hurst et al., 2005) . PNU-120596 has also been reported to enhance the increase in dopamine release in the mPFC induced by choline and an α7 nAChR agonist (compound A; (R)-N-(1-azabicyclo[2.2.2] oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide); it was also shown that PNU-120596 (1 mg/kg; s.c.) when administered systemically (but not locally) also produced an increase in dopamine overflow in the mPFC in the absence of an agonist (Livingstone et al., 2009) . This is of importance, as it has been previously shown that attentional set-shifting performance is dependent upon the mPFC (Birrell and Brown, 2000) and that dopamine plays a pivotal role in cognition (Goldman-Rakic et al., 2004) . Indeed, we have found the PCP-induced deficit in novel object recognition memory is accompanied by impaired dopamine neurotransmission in the PFC during the retention trial of the task (Snigdha et al., 2008) . This result was also recently confirmed in a second study in our laboratory (McLean, unpublished observations).
In conclusion, PNU-120596 reversed a sub-chronic PCPinduced deficit in attentional set-shifting ability. To our knowledge this is the first study to investigate an α7 nAChR PAM in the attentional set-shifting task. It is suggested from other studies that these compounds may exert their cognitive-enhancing effects by potentiating the effects of endogenous acetylcholine and increasing levels of dopamine and acetylcholine in the prefrontal cortex.
